The purpose of this study is a long-term, observational study of Abatacept in patients with Psoriatic Arthritis, a chronic inflammatory disorder.
Study Type
OBSERVATIONAL
Enrollment
190
Local Institution - 0001
Nuremberg, Germany
Disease Activity index for PSoriatic Arthritis (DAPSA)
Time frame: 12 months
Participant retention rate
Time frame: 12 Months
Proportion of concomitant treatment given
Time frame: 12 Months
Initial dosage of Abatacept given
Time frame: At Treatment Initiation
Frequency of Abatacept administration
Time frame: 12 months
Descriptive Analysis: Reasons for Abatacept initiation
Time frame: up to 2 years prior to treatment
Proportion of patients previously receiving by type of Disease modifying anti-rheumatic drug (DMARD)
Time frame: up to 2 years prior to treatment
Descriptive Analysis: Socio-Demographics at Treatment Initiation
Time frame: At Treatment Initiation
Descriptive Analysis: Disease history at Treatment initiation
Time frame: Prior to treatment
Incidence of Risk factors and Comorbidities
Time frame: At Treatment Initiation
Descriptive Analysis: Baseline Characteristics
Time frame: up to 2 years prior to treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Descriptive Analysis: Change in participant characteristics and symptoms
Time frame: 12 months
Proportion of Rheumatologist: Geography
Time frame: up to 2 months prior to treatment to 12 months post treatment
Proportion of Rheumatologist: Type of Institution
Time frame: up to 2 months prior to treatment to 12 months post treatment
Proportion and type of treatment after abatacept discontinuation
Time frame: 12 months
Proportion of reasons for abatacept discontinuation and initiation of new therapy
Time frame: 12 Months